Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer
about
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsA phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and AutophagyTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?Tumor-stromal interactions in breast tumor progression--significance of histological heterogeneity of tumor-stromal fibroblasts.Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer TreatmentBortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case reportDownregulation of PKCζ/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.
P2860
Q34218976-DB8D6D4E-A69E-4911-9BC9-43CF927A2BECQ35058595-5EB46324-A285-447A-9B74-F631CDB8DAD0Q35790990-62A79BF4-3AF8-4FDB-88D4-CCE3C50213B6Q35891380-2601FAC9-C233-4C1D-AC32-5ED61645E684Q36225532-3F34AFE7-2B86-4EB2-8774-12A4E30F6B36Q36999705-79BE3091-A122-44FD-85E8-9024D0BE03C1Q38072443-C8C98129-684A-4F6B-933E-ACFF90A44303Q39021534-06E809BE-BDAA-43F6-96A2-0A3FA0CEDE68Q39084493-39B3F916-7857-4957-8234-45E7C1B445EAQ40648639-091CDF7C-A579-48C1-BDBD-BD3DC44DB0C2Q41435784-5C3E81B6-6D15-44DF-AD13-890BAD5581E0Q42511544-5D666EBA-A3CF-4A17-81E1-5B1B3948F21F
P2860
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@ast
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@en
type
label
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@ast
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@en
prefLabel
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@ast
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@en
P2093
P2860
P1476
Phase-I/II study of bortezomib ...... ced non-small-cell lung cancer
@en
P2093
Bilal Piperdi
Kendra Bradley
Lloyd Hutchinson
Meredith Hanrahan-Boshes
Roman Perez-Soler
Venu Bathini
William V Walsh
Zheng Zhou
P2860
P304
P356
10.1097/JTO.0B013E31824DE2FA
P577
2012-06-01T00:00:00Z